BioSpace News Archive

Mymetics Corporation announced that Stallergenes Greer, a worldwide leader in allergen immunotherapy and Anergis, a leader in ultra-fast AIT research and development, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.

Neutra Corp. has completed payments on the last of its convertible debts with one of its lenders, demonstrating the company’s strength and preparing it for future growth opportunities.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced the appointment of Dr. Jack Reich to the Board of Directors. The appointment increases the Board to seven members.

The 73rd World Health Assembly was held in a special period of time when the outbreak of COVID-19 put the world in a complex situation, and the virus is still raging worldwide.

Genestack Ltd. announced that its flagship multi-omics data catalogue, curation and integrative search product, Omics Data Manager, has been licensed and implemented by AstraZeneca.

Observed clinical activity, including durable and complete tumour responses, suggests that MTL‑CEBPA may increase the effectiveness of sorafenib standard of care

Results demonstrate inverse relationship between presence of ecDNA and biomarkers that predict response to pembrolizumab in recurrent or metastatic gastric cancer

Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced management’s participation in the following investor and industry conferences in June

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the company will be participating in the upcoming Jefferies Virtual Healthcare Conference. TELA Bio’s management is scheduled to present on Tuesday, June 2, 2020 at 9:00 AM Eastern Daylight Time (E

Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months